Deal Announcements

ReVance Therapeutics Raises 4th Venture Capital Round

Wednesday, December 30, 2009 5:58:00 AM PDT | VentureDeal Staff

Newark, California  --  Biotechnology company ReVance Therapeutics has secured $25.62 million in its series D round of institutional venture capital investment.

ReVance is developing a topical botulinum toxin to eliminate the need for needles in delivering facial aesthetics and hyperhidrosis.

Investors in the round were not detailed, nor was how the company intends to use the investment proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1